Can Stem Cell Therapy Reset the Immune System in Lupus and Autoimmune Disease?

If you’re living with lupus, you already know the exhausting rhythm of flares and remissions — the joint pain that arrives without warning, the fatigue that doesn’t lift with rest, the medications that manage symptoms but never quite address the root problem. For many patients and caregivers, the search for something more than symptom control eventually leads to a question: could stem cell therapy actually help “reset” a misfiring immune system?

It’s a compelling idea, and one that researchers are actively investigating. Mesenchymal stem cells (MSCs) have well-documented immune-regulating properties, and early clinical studies in lupus and other autoimmune conditions have produced encouraging — though still preliminary — results. This article looks at what the science actually shows, where the term “reset” fits (and where it doesn’t), and what a realistic view of this emerging field looks like.

1. Lupus involves a genuine immune malfunction, not just symptoms — T-cells and B-cells lose their ability to distinguish the body’s own tissue from foreign threats, driving chronic inflammation that conventional treatment manages but doesn’t correct at the root.
2. MSCs work through immune signaling, not tissue replacement — their therapeutic interest lies in cytokine regulation and the ability to encourage regulatory T-cells, which can help calm an overactive immune response.
3. “Immune reset” is a conceptual shorthand, not a proven mechanism — early research points to immune recalibration through Treg support, cytokine balance, and T-cell/B-cell modulation, but durability and permanence are still being studied.
4. Clinical trial data is encouraging but early-stage — studies report improved disease activity scores and reduced proteinuria in lupus nephritis, alongside a generally favorable short-term safety profile, though relapse after initial response has been documented in some patients.
5. This remains investigational, not a cure or first-line treatment — MSC therapy for lupus hasn’t received full regulatory approval as standard care in most jurisdictions, so it should be considered alongside a qualified physician’s guidance rather than as a replacement for conventional treatment.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system loses its ability to distinguish the body’s own tissue from foreign invaders. Instead of protecting the body, immune cells produce autoantibodies that attack healthy tissue — commonly affecting the skin, joints, kidneys, heart, and nervous system.

At the cellular level, lupus involves dysregulated T-cells and B-cells (the immune system’s coordinators and antibody factories, respectively). B-cells overproduce autoantibodies, while regulatory T-cells — the cells normally responsible for keeping immune activity in check — become less effective. The result is chronic, widespread inflammation that can flare unpredictably.

Common symptoms include:

• Joint pain and swelling
• Persistent fatigue
• Skin rashes, including the characteristic “butterfly” facial rash
• Kidney inflammation (lupus nephritis)
• Fever and sensitivity to sunlight
• Hair loss and mouth sores

Conventional treatment relies on immunosuppressants and corticosteroids, which manage inflammation but don’t correct the underlying immune imbalance — and often carry significant long-term side effects. This gap is part of why researchers have turned to cell-based approaches like MSC therapy.

Mesenchymal stem cells (MSCs) are adult stem cells that can be sourced from bone marrow, umbilical cord tissue, or adipose (fat) tissue. Unlike embryonic stem cells, MSCs don’t primarily work by becoming replacement tissue. Their therapeutic interest in autoimmune disease comes from something different: their immunomodulatory signaling.

MSCs release a wide range of cytokines and growth factors that can influence how immune cells behave. In laboratory and preclinical studies, MSCs have been shown to:

• Suppress excessive T-cell proliferation
• Encourage the development of regulatory T-cells (Tregs), which help dampen autoimmune activity
• Reduce pro-inflammatory cytokine production
• Modulate B-cell activity, potentially reducing autoantibody output

This immune-regulating profile is why mesenchymal stem cell therapy has become a focus of research not just for lupus, but across a range of autoimmune and inflammatory conditions. It’s worth noting that MSCs don’t act as a blanket immune suppressor the way many pharmaceutical options do — instead, researchers are interested in their ability to selectively calm an overactive response while leaving broader immune defenses intact. That distinction is central to the “reset” language often used to describe this research, though it’s an area still being actively studied rather than a settled mechanism.

The term “immune reset” is more of a conceptual shorthand than a precise clinical description, but it points to a real area of investigation: the idea that MSCs might help recalibrate immune tolerance rather than simply suppress symptoms.

Several proposed mechanisms are under study:

Immune tolerance induction. MSCs appear to promote a shift toward regulatory T-cells, which are responsible for teaching the immune system to tolerate the body’s own tissue. In lupus, Treg function is often impaired — so supporting this population is a key area of interest.

Cytokine regulation. MSCs secrete anti-inflammatory signaling molecules that can help rebalance the cytokine environment, shifting it away from the pro-inflammatory state that drives lupus flares.

T-cell and B-cell modulation. Research suggests MSCs can inhibit the proliferation of autoreactive T-cells and reduce the antibody-producing activity of B-cells — the two cell types most directly responsible for lupus’s autoimmune attacks. A review discussing cell therapies for SLE noted that MSC infusion in preclinical lupus models suppressed markers of kidney inflammation, reduced autoantibody production, and improved survival, in part through effects on immune cell activation (Deng et al., Frontiers in Immunology discussion cited in Cell Therapies for SLE review, Stem Cells Translational Medicine, 2024).

Tissue repair support. Beyond immune signaling, MSCs are also studied for their potential to support repair of tissue already damaged by chronic inflammation, particularly in the kidneys in cases of lupus nephritis.

It’s important to be clear that “reset” does not mean cure. Current evidence suggests MSC therapy may help recalibrate certain immune pathways in some patients, with effects that in published trials have lasted months to a few years — not necessarily a permanent correction. Researchers are still working to understand durability, optimal dosing, and which patients respond best.

Human trials in lupus, particularly using umbilical cord-derived MSCs, have been ongoing for over a decade, largely centered around research groups in China.

A multicenter clinical study registered with ClinicalTrials.gov (NCT01741857) treated 40 patients with active, treatment-resistant SLE using two intravenous infusions of allogeneic umbilical cord MSCs. Over 12 months of follow-up, roughly a third of patients achieved a major clinical response and just over a quarter achieved a partial response, with disease activity scores and autoantibody levels improving at follow-up (Wang et al., 2014, published in Arthritis Research & Therapy). The therapy was reported as well tolerated, though several patients relapsed after six months, suggesting repeat treatment may be necessary for some.

A 2020 meta-analysis reviewing ten studies — including four randomized controlled trials — found that MSC-treated SLE patients showed lower proteinuria (a marker of kidney involvement) and lower disease activity index scores compared to control groups, along with a lower rate of adverse events (Wang et al., 2020, Stem Cells International).

A broader systematic review and meta-analysis of randomized controlled trials across five autoimmune conditions — including SLE, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis — similarly reported measurable improvements in disease activity scores and inflammatory markers following MSC transplantation, while noting that further high-quality trials are still needed (2022, Frontiers in Immunology).

Separately, a study identifying prognostic factors for MSC response in SLE followed 69 patients and found that 58% achieved low disease activity and 23% achieved clinical remission at various points during a year of follow-up, with response influenced by factors such as patient age and prior treatment history (Deng et al., 2019, Frontiers in Immunology).

Collectively, these studies support cautious optimism: stem cell therapy for lupus shows promise in early-to-mid-stage clinical research, but it remains investigational. It has not received full regulatory approval as a standard lupus treatment in most jurisdictions, and larger, longer-term controlled trials are still needed to confirm efficacy, durability, and ideal patient selection.

Potential benefits reported in research:

• Reduction in disease activity scores (SLEDAI) in several trials
• Decreased proteinuria in patients with lupus nephritis
• Generally favorable short-to-medium-term safety profile in published studies
• A treatment approach that targets immune regulation rather than broad suppression

Limitations and open questions:

• Most large trials have come from a small number of research centers, so results may not generalize broadly yet
• Relapse after initial improvement has been reported in a meaningful subset of patients, suggesting repeat treatment may be needed
• Long-term safety and durability data beyond a few years remain limited
• Individual response varies significantly, and clinical trials haven’t yet clarified which patients are most likely to benefit
• This is not currently established as a first-line or FDA-approved treatment for lupus in most countries; it remains part of ongoing clinical investigation

Framing this honestly matters. Reputable sources in the stem cell therapy for autoimmune diseases space, including researchers who developed these trials, describe MSC therapy as promising rather than proven — an important distinction for any patient weighing their options.

While specifics vary by clinic and individual case, a typical patient journey generally includes an initial consultation and medical history review, diagnostic testing to assess current disease activity and organ involvement, and a discussion of whether the patient is an appropriate candidate for investigational MSC therapy alongside their existing treatment plan.

Treatment itself usually involves one or more intravenous infusions of MSCs, most commonly from umbilical cord or bone marrow sources, followed by a monitoring period to track disease activity markers, kidney function (where relevant), and any adverse effects. Because MSC therapy for lupus is still investigational, follow-up and long-term monitoring are especially important parts of the process.

Patients considering this route should also factor in stem cell therapy cost, which varies depending on the source of cells, number of infusions, and the extent of pre- and post-treatment monitoring involved.

Living with lupus or another autoimmune disease can make the promise of an “immune reset” feel like exactly what you’ve been waiting for. The research is genuinely encouraging, but it’s still evolving — and any responsible clinic should be upfront that this is an investigational approach studied alongside, not necessarily instead of, conventional care.

If you’re exploring whether MSC therapy might be relevant to your situation — whether for lupus or a related condition such as rheumatoid arthritis or multiple sclerosis — our team at Viezec can walk you through the current evidence, what realistic outcomes look like, and whether you may be a candidate. We encourage you to contact us to schedule a personalized consultation with our specialists.

• Wang, D., et al. (2014). Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Research & Therapy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060570/ (ClinicalTrials.gov: NCT01741857)
• Wang, L., et al. (2020). Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. Stem Cells International. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157802/
• Deng, D., et al. (2019). Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. Frontiers in Immunology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525791/
• Current cell therapies for systemic lupus erythematosus. (2024). Stem Cells Translational Medicine. https://academic.oup.com/stcltm/article/13/9/859/7699415
• An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis. https://pmc.ncbi.nlm.nih.gov/articles/PMC8010225/